FORM	4
------	---

1	Check this box if no
	longer subject to
	Section 16. Form 4 or
	Form 5 obligations may
	continue. See
	*

(Duint on Tom - Door on

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Instruction 1(b). Company Act of 1940

1. Name and Address of Reporting Person [*] Cohen Yuval	2. Issuer Name and Ticker or Trading Symbol Corbus Pharmaceuticals Holdings, Inc. [CRBP]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_Director10% Owner				
(Last) (First) C/O CORBUS PHARMACEUTICA HOLDINGS, INC, 500 RIVER RID	LS	3. Date of Earliest Transaction (Month/Day/Year) 03/06/2020					X_Officer (give title below) Other (specify below) Chief Executive Officer				
(Street) NORWOOD, MA 02062	4	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acqu					s Acqu	ired, Disposed of, or Beneficially Owned	d		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	(Instr. 8)		4. Securi (A) or Di (Instr. 3,	isposed of	f (D)	Transaction(s) (Instr. 3 and 4)		Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price		(I) (Instr. 4)	(1130.4)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Person
this for

Persons who respond to the collection of information contained in SEC 1474 (9-02) this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(<i>e.g.</i> , puts, calls, warrants, options, convertible securities)															
Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	tion)	5. Number Derivative Securities Acquired (or Dispose (D) (Instr. 3, 4, and 5)	A) d of	Expiration I (Month/Day	xpiration Date o Month/Day/Year) S		ate of Underlying Year) Securities		Derivative Security (Instr. 5)	Securities Beneficially Owned Following	Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficial Ownership (Instr. 4)
				Code	V	(A)		Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)		
Stock Option(right to buy)	\$ 4.53	03/06/2020		А		639,000		<u>(1)</u>	03/06/2030	Common Stock	639,000	\$ 0	639,000	D		

Reporting Owners

	Relationships						
Reporting Owner Name / Address		10% Owner	Officer	Other			
Cohen Yuval C/O CORBUS PHARMACEUTICALS HOLDINGS, INC 500 RIVER RIDGE DRIVE NORWOOD, MA 02062	Х		Chief Executive Officer				

Signatures

/s/ Yuval Cohen	03/09/2020
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on March 6, 2021, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on April 6, 2021.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.